Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Blood Glucose

Blood Glucose

Blood Glucose: A measure of the concentration of glucose in the blood.
Glucose, the primary source of energy for the body's cells, is transported through the bloodstream.
Maintaining normal blood glucose levels is crucial for health and is regulated by insulin and other hormones.
Imbalances in blood glucose can lead to conditions like diabetes, hypoglycemia, and hyperglycemia.
Effective management of blood glucose is essential for optimal health and disease prevention.

Most cited protocols related to «Blood Glucose»

1
Predictive Model for Atrial Fibrillation
Cited 51 times
Means and standard deviation and frequency distribution of relevant covariates were calculated by cohort and race. We initially ran cohort‐ and race‐specific Cox proportional hazard models to assess individual predictors of AF after age‐ and sex‐adjustment in each cohort up to 7 years of follow‐up. Variables considered included age, sex, height, weight, current smoking, systolic and diastolic blood pressure, use of antihypertensive medication, history of diabetes, fasting blood glucose, estimated glomerular filtration rate (eGFR) <60 mL/kg per m2,20 (link) total blood cholesterol, HDL cholesterol, triglycerides, heart rate, electrocardiographic‐derived left ventricular hypertrophy, PR interval, history of coronary artery bypass graft (CABG), history of heart failure, history of myocardial infarction, and history of stroke. We selected as candidate predictors for our pooled model any variable significantly associated with AF (P<0.05) in at least 2 of the 3 cohorts, and ran the final Cox proportional hazards model on our participant‐specific pooled data using backward selection of variables (P<0.05 to remain in the model). Age, sex, and race interactions were tested, as was the assumption of proportional hazards. Model‐based individual 5‐year risk of AF was calculated. We evaluated model performance using the C‐statistic,21 (link) discrimination slopes,22 (link) and Nam and D'Agostino's modified Hosmer‐Lemeshow chi‐square statistic for survival analysis.23 To facilitate the use of our score in those clinical settings with limited access to electrocardiograms or blood tests, we first developed a predictive model that did not require information from electrocardiogram and blood tests (which we labeled “simple model”). We then developed a more complex model adding electrocardiographic variables and blood tests (labeled “augmented model”). Variables were retained in the models if they were significantly associated with AF incidence (P<0.05). We calculated the added predicted value of the augmented model versus the simple model with the increment in the C‐statistic and the categorical net reclassification improvement (NRI) using the following risk categories: <2.5%, 2.5% to 5%, >5%.22 (link)
Alonso A., Krijthe B.P., Aspelund T., Stepas K.A., Pencina M.J., Moser C.B., Sinner M.F., Sotoodehnia N., Fontes J.D., Janssens A.C., Kronmal R.A., Magnani J.W., Witteman J.C., Chamberlain A.M., Lubitz S.A., Schnabel R.B., Agarwal S.K., McManus D.D., Ellinor P.T., Larson M.G., Burke G.L., Launer L.J., Hofman A., Levy D., Gottdiener J.S., Kääb S., Couper D., Harris T.B., Soliman E.Z., Stricker B.H., Gudnason V., Heckbert S.R, & Benjamin E.J. (2013). Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2(2), e000102.
Full text: Click here
Publication 2013
Antihypertensive Agents BLOOD Blood Glucose Cerebrovascular Accident Cholesterol Congestive Heart Failure Coronary Artery Bypass Surgery Diabetes Mellitus Discrimination, Psychology Electrocardiogram Electrocardiography Glomerular Filtration Rate Hematologic Tests High Density Lipoprotein Cholesterol Left Ventricular Hypertrophy Myocardial Infarction Pressure, Diastolic Rate, Heart Systole Triglycerides
2
Multimodal Glycemic Monitoring in Clinical Trials
Cited 45 times
Measures of glycemia included continuous interstitial glucose monitoring (CGM) (CGMS; Medtronic Minimed, Northridge, CA), which measures glucose levels every 5 min and was performed for at least 2 days at baseline and then every 4 weeks during the next 12 weeks. For calibration purposes and as an independent measure of glycemia, subjects performed eight-point (premeal, 90 min postmeal, prebed, and at 3:00 a.m.) self-monitoring of capillary glucose with the HemoCue blood glucose meter (Hemocue Glucose 201 Plus; Hemocue, Ángelholm, Sweden) during the 2 days of CGM. As a third and independent measure of glycemia, subjects were asked to perform seven-point (same as the eight-point profile above without the 3:00 a.m. measurement) fingerstick capillary glucose monitoring (OneTouch Ultra; Lifescan, Milipitas, CA) for at least 3 days per week, at times when CGM was not being performed, for the duration of the study. The results from the CGM and fingerstick monitoring were downloaded from their respective meters and exported to the data coordinating center. To be acceptable for analysis, the CGM data had to include at least one successful 24-h profile out of the 2–3 days of monitoring with no gaps >120 min and a mean absolute difference compared with the Hemocue calibration results <18%, as recommended by the manufacturer.
Blood samples for A1C were obtained at baseline and monthly for 3 months. The blood samples were frozen at −80° C and were sent on dry ice by overnight shipment to the central laboratory. Samples were analyzed with four different DCCT-aligned assays, including a high-performance liquid chromatography assay (Tosoh G7; Tosoh Bioscience, Tokyo, Japan), two immunoassays (Roche A1C and Roche Tina-quant; Roche Diagnostics), and an affinity assay (Primus Ultra-2; Primus Diagnostics, Kansas City, MO). The mean A1C value was used. The laboratory assays were approved by the National Glycohemoglobin Study Program (10 (link)) and have intra- and interassay coefficients of variation <2.5% for low and high values. The assays were highly intercorrelated with R2 values of 0.99 and slopes of ∼1.0 and intercepts between 0.01 and 0.18. Any samples that demonstrated “aging peaks” on high-performance liquid chromatography, evidence of degradation during storage and/or shipment, were considered unacceptable for analysis. One center in Asia was unable to store samples acceptably, resulting in samples that could not be assayed for A1C. The center was eliminated from the study.
Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D, & Heine R.J. (2008). Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care, 31(8), 1473-1478.
Publication 2008
BLOOD Blood Glucose Capillaries Diagnosis Dry Ice Freezing Glucose Hemoglobin, Glycosylated High-Performance Liquid Chromatographies Immunoassay Methamphetamine
3
Mild Gestational Diabetes Mellitus: Evaluation of Treatment
Cited 37 times
Women were invited to participate in this study if, between 24 weeks 0 days and 30 weeks 6 days of gestation, they had a blood glucose concentration between 135 and 200 mg per deciliter (between 7.5 and 11.1 mmol per liter) 1 hour after a 50-g glucose loading test. Women were excluded if they had preexisting diabetes, an abnormal result on a glucose screening test before 24 weeks of gestation, prior gestational diabetes, a history of stillbirth, multifetal gestation, asthma, or chronic hypertension; if they were taking corticosteroids; if there was a known fetal anomaly; or if imminent or preterm delivery was likely because of maternal disease or fetal conditions. All the women who pa rticipated in the study provided written informed consent. The study was approved by the human subjects committee at each participating center.
After an overnight fast, eligible women completed a blinded 3-hour 100-g oral glucose-tolerance test. Samples were analyzed at a central laboratory, and results were forwarded to the data coordinating center. Mild gestational diabetes mellitus was defined as a fasting glucose level of less than 95 mg per deciliter (5.3 mmol per liter) and two or three timed glucose measurements that exceeded established thresholds: 1-hour, 180 mg per deciliter (10.0 mmol per liter); 2-hour, 155 mg per deciliter (8.6 mmol per liter); and 3-hour, 140 mg per deciliter (7.8 mmol per liter).10 (link) Women who met these criteria were randomly assigned by the coordinating center, with the use of the simple urn method,11 (link) stratified by clinical center. The urn method minimizes the degree of imbalance in the number of patients assigned to each group by increasing the probability of a patient’s assignment to the group that has previously been selected least often. Women were assigned to receive either formal nutritional counseling and diet therapy,12 (link) along with insulin if required (treatment group) or usual prenatal care (control group). In addition, a cohort of women who had a positive result on the 50-g glucose loading test but a normal result on a subsequent oral glucose-tolerance test and who were matched with the study cohort according to race and body-mass index (the weight in kilograms divided by the square of the height in meters), dichotomized as less than 27 or 27 or more, were enrolled by the data coordinating center in the group that received usual prenatal care. By including this group of women who did not have gestational diabetes mellitus, the patients, their caregivers, and the study staff were unaware of whether women in the control group met the criteria for the diagnosis of mild gestational diabetes mellitus. Women with a fasting glucose level of 95 mg per deciliter or more on the diagnostic oral glucose-tolerance test were excluded from the study, and their condition was made known to their health care providers.
Ultrasonography was performed in all subjects before the oral glucose-tolerance test to confirm the gestational age. Women who were receiving treatment performed daily self-monitoring of their blood glucose (fasting and 2-hour postprandial measurements) with the use of a portable memory-based reflectance meter. Insulin was prescribed if the majority of fasting values or postprandial values between study visits were elevated (fasting glucose level, ≥95 mg per deciliter or 2-hour postprandial glucose level, ≥120 mg per deciliter [6.7 mmol per liter]). If, during a prenatal visit, there was a clinical suspicion of hyperglycemia in a patient who was in the control group, the blood glucose level could be measured at the discretion of the provider. If a random blood glucose level of 160 mg per deciliter (8.9 mmol per liter) or more or a fasting glucose level of 95 mg per deciliter or more was detected, the patient’s caregiver initiated treatment and notified the local principal investigator and study personnel.
Nonstress testing, biophysical profile testing, and ultrasonography to assess fetal growth were not performed routinely in the treatment group but were reserved for standard obstetrical indications. However, all the women who were enrolled in the study were instructed regarding the daily assessment of fetal activity.13 (link) If delivery was not the result of spontaneous labor, the rationale for the timing and method of delivery was documented.
Landon M.B., Spong C.Y., Thom E., Carpenter M.W., Ramin S.M., Casey B., Wapner R.J., Varner M.W., Rouse D.J., Thorp JM J.r., Sciscione A., Catalano P., Harper M., Saade G., Lain K.Y., Sorokin Y., Peaceman A.M., Tolosa J.E, & Anderson G.B. (2009). A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes. The New England journal of medicine, 361(14), 1339-1348.
Publication 2009
Adrenal Cortex Hormones Asthma Blood Glucose Blood Glucose Self-Monitoring Care, Prenatal Diabetes Mellitus Diagnosis Fetal Anomalies Fetal Diseases Fetal Growth Fetal Movement Gestational Age Gestational Diabetes Glucose High Blood Pressures Homo sapiens Hyperglycemia Index, Body Mass Insulin Memory Mothers Obstetric Delivery Obstetric Labor Oral Glucose Tolerance Test Patients Pregnancy Premature Birth Therapy, Diet Ultrasonography Woman
4
Comprehensive Baseline Data Collection for Biobank
Cited 30 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Antihypertensive Agents Blood Glucose Body Weight Cardiovascular Diseases Childbirth Complete Blood Count Coronary Angiography Diagnosis Drug Reaction, Adverse Eating Echocardiography Enzymes Ethanol High Blood Pressures Index, Body Mass Japanese Kidney Lipids Liver Function Tests Malignant Neoplasms Operative Surgical Procedures Pharmaceutical Preparations Pharmacotherapy Pressure, Diastolic Radiotherapy Systole Systolic Pressure Therapeutics Tumor Markers Urinalysis Woman
5
Pediatric Acute Kidney Injury Management
Cited 27 times
The protocol was discussed in multiple sessions with the resident doctors and nurses posted in PICU and Emergency units on the first day of every month throughout the duration of the study. The investigator visited the Emergency and PICU at least twice a day and as and when needed to ensure strict implementation of protocol. Phone number of the investigator was made available in both the units. Posters of protocol design were displayed on the notice boards of the Emergency and PICU. Weekly checks on protocol adherence were carried out by the co-investigators.
Clinical data (respiratory rate, pulse, capillary refill, blood pressure, hydration status, fluid intake, urine output) were continuously recorded, and the values were entered in a pre-designed monitoring sheet. Blood glucose (capillary or venous) was checked every hour and blood gas every 4 h. Urea, creatinine, and electrolytes were measured every 4–8 hourly. We used the enzymatic method of creatinine estimation to prevent interference with non-creatinine products.
For KDIGO staging, if pre-admission creatinine values were available, either the single value or the least value (in case of multiple values) during the previous 3 months was taken as baseline value. If baseline creatinine was unavailable, then a GFR of 127 ml/min and 103 ml/min were assumed for children above 1 year and below 1 year respectively to calculate creatinine using Schwartz formula (Additional file 1: Appendix).
The need for RRT was assessed daily. In addition to renal failure-related data points, the duration of mechanical ventilation (MV), length of ICU and hospital stays from time of study enrolment, and in-hospital mortality were recorded.
Williams V., Jayashree M., Nallasamy K., Dayal D, & Rawat A. (2020). 0.9% saline versus Plasma-Lyte as initial fluid in children with diabetic ketoacidosis (SPinK trial): a double-blind randomized controlled trial. Critical Care, 24, 1.
Full text: Click here
Publication 2020
Blood Blood Glucose Blood Pressure Capillaries Child Creatinine Electrolytes Emergencies Enzymes Kidney Failure Mechanical Ventilation Nurses Physicians Pulse Rate Respiratory Rate Urea Urine Veins

Most recents protocols related to «Blood Glucose»

1
Glucose Tolerance Evaluation of Peptides
Not available on PMC !

Example 14

CD1 mice were fasted for overnight and then administrated with certain amount of peptides through either i.v. or s.c. route. After 6 hours, mice were orally or intraperitoneally administrated with bolus dose of glucose solution at 2 g/kg body mass at concentration of 100 mg/mL and their tail blood glucose levels were measured before (0 min) and after glucose challenge for 2 to 3 hours.

Exemplary data for mTA4 and mTA37 (see Table 6) are shown in FIG. 13 (n=5 for both). Both mTA4 and mTA37 are functional in wild-type mice. The data indicate increased oral glucose tolerance after administration of mTA. OGTT results for mTA4 demonstrated that mTA4 had a greater effect than exendin-4 at 6 hours after a single i.v. dose of mTA.

US11865160B2. Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof (2024-01-09). THE SCRIPPS RESEARCH INSTITUTE [US]. Inventors: Weijun Shen [US], Pengyu Yang [US], Huafei Zou [US], Peter G. Schultz [US].
Full text: Click here
Patent 2024
Blood Glucose Exenatide Glucose Glucose Tolerance Test Human Body Mice, House Oral Glucose Tolerance Test Peptides Suby's G solution Tail
2
GABA Enhances IL-2 Reversal of T1D
Not available on PMC !

Example 5

Cotreatment with GABA Enhances the Ability of IL-2 to Reverse T1D.

Treatment with IL-2 has been shown to have a modest ability to reverse hyperglycemia in newly diabetic NOD mice. We now have data showing that administration of IL-2 with GABA can enhance its therapeutic effect, and more efficiently reverse hyperglycemia. In the FIG. 11, only one of three newly diabetic NOD mice treated with IL-2 became normoglycemic (blood glucose below 250 mgs/dl) (individual mice represented by black symbols). In contrast two of two newly diabetic mice treated with IL-2+GABA became normoglycemic (open symbols).

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

US11872200B2. GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes (2024-01-16). The Regents of the University of California [US]. Inventors: Daniel L Kaufman [US], Jide Tian [US].
Full text: Click here
Patent 2024
Blood Glucose Combined Modality Therapy GABA Agonists gamma Aminobutyric Acid Hyperglycemia Light Metabolic Syndrome X Mice, Inbred NOD Mus Therapeutic Effect
3
Chronic Effects of GLP1R Agonists on Obesity
Not available on PMC !

Example 15

Diet Induced Obese (DIO) mice were purchased from Charles River and administrated by s.c. route with GLP1R agonist or GLP1R/GCGR dual agonist. Mouse body weight and food intake were monitored daily for 2 weeks, and followed before (5 days in total) and during treatment (5-weeks in total). After 5 weeks, mice were sacrificed and visceral fat mass were taken out and weighed.

Dose dependent weight loss induced by mTA4 or mTA37 (see Table 6) is shown in FIG. 14. Chronic effect on body weight loss with daily administration of mTA4 or mTA37 for 5 weeks and cumulative food intake for 2 weeks are shown in FIG. 15. Increased intra-peritoneal glucose tolerance after daily administration of mTA4 or mTA37 for 5 weeks is shown in FIG. 16. Reduced fasting blood glucose levels after daily administration of mTA4 or mTA37 for 5 weeks is shown in FIG. 17.

US11865160B2. Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof (2024-01-09). THE SCRIPPS RESEARCH INSTITUTE [US]. Inventors: Weijun Shen [US], Pengyu Yang [US], Huafei Zou [US], Peter G. Schultz [US].
Full text: Click here
Patent 2024
Blood Glucose Body Weight Diet Eating Glucose Immune Tolerance Injections, Intraperitoneal Mice, Obese Mus Rivers Visceral Fat
4
GR Compounds' Effects on Mouse Blood Glucose
Not available on PMC !

Example 26

33 ICR mice were randomly divided into 11 groups, i.e. normal saline group, 1.8 mg/kg dexamethasone acetate group (Dex), CK, IB, IC, ID, IVA, IH, IJ, IK and IL were respectively given 225 mg/kg. The mice were intragastric administration for 6 consecutive days, fasting was started at about 8:00 in the morning on the sixth day, and blood glucose in caudal vein was measured at about 4:00 in the next day.

TABLE 5
Blood glucose data of GR series compounds
GroupBlood glucose (mmol/L)
Blank group3.05 ± 0.11
Dex 5.78 ± 0.36**
CK3.18 ± 0.28
IB3.10 ± 0.19
IC3.25 ± 0.26
ID2.79 ± 0.56
IVA3.02 ± 0.23
IH2.98 ± 0.37
IJ3.11 ± 0.43
IK3.09 ± 0.28
IL3.03 ± 0.21
Note:
compared to blank group,
* P < 0.05,
**P < 0.01

Blood glucose data showed that compared with the blank control group, dexamethasone could increase blood glucose in mice, while no blood glucose related changes were caused by CK and GR derivatives.

US11866458B2. Panaxadiol glycoside derivative and preparation method and application thereof (2024-01-09). SUZHOU JI ER BIOLOGICAL MEDICINE CO., LTD. [CN]. Inventors: Quanhai Liu [CN], Jun Zhang [CN].
Full text: Click here
Patent 2024
Blood Glucose derivatives Dexamethasone dexamethasone acetate IL21 protein, human Mice, House Mice, Inbred ICR Normal Saline Veins
5
Oral Insulin Formulation with FDKP Salt
Not available on PMC !

Example 11

Capsules containing the FDKP salt and insulin are taken before a meal. The exact dosage is patient-specific, but generally on the order of approximately 10-150 units of insulin is administered per dose. The subsequent insulin absorption attenuates post-prandial blood glucose excursions. This oral insulin formulation is used to replace pre-meal insulin injections in patients with diabetes. Additionally, insulin absorbed through the gastrointestinal tract mimics endogenous insulin secretion. Endogenous insulin is secreted by the pancreas into the portal circulation. Insulin absorbed following oral administration also goes directly to the portal circulation. Thus, the oral route of insulin administration delivers insulin to its site of action in the liver, offering the potential to control glucose levels while limiting systemic exposure to insulin. Oral insulin delivery using a combination of insulin and the diacid form of FDKP is hindered by the poor solubility of the FDKP diacid in the low pH environment of the gastrointestinal tract. The FDKP salts, however, provide a local buffering effect that facilitates their dissolution in low pH.

US11872265B2. Diketopiperazine salts for drug delivery and related methods (2024-01-16). MannKind Corporation [US]. Inventors: Andrea Leone-Bay [US], Destardi Moye-Sherman [US], Bryan R. Wilson [US].
Full text: Click here
Patent 2024
3,6-bis(N-fumaryl-N(n-butyl)amino)-2,5-diketopiperazine Administration, Oral Blood Glucose Capsule Diabetes Mellitus Gastrointestinal Tract Glucose Insulin Insulin Secretion Liver Obstetric Delivery Pancreas Patients Salts Sodium Chloride

Top products related to «Blood Glucose»

1
Streptozotocin (stz) by Merck Group
Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, India, Japan, Macao, Canada, France, Italy, Switzerland, Egypt, Poland, Hungary, Denmark, Indonesia, Singapore, Sweden, Belgium, Malaysia, Israel, Spain, Czechia
STZ is a laboratory equipment product manufactured by Merck Group. It is designed for use in scientific research and experiments. The core function of STZ is to serve as a tool for carrying out specific tasks or procedures in a laboratory setting. No further details or interpretation of its intended use are provided.
2
Accu chek by Roche
Sourced in Germany, Switzerland, United States, United Kingdom, Brazil, Australia, China, India, Spain, Canada, France, Hungary, Japan, Thailand, Belgium, Denmark
The Accu-Chek product line from Roche is a suite of blood glucose monitoring systems designed for use in clinical and personal settings. The core function of the Accu-Chek devices is to accurately measure and display blood glucose levels.
3
Accu chek performa by Roche
Sourced in Germany, United States, Switzerland, Australia, France, Brazil, China, Japan, Argentina, Thailand, United Kingdom, Canada
The Accu-Chek Performa is a blood glucose monitoring system designed to measure the level of glucose in the user's blood. It provides accurate and reliable readings to help individuals manage their diabetes.
4
D glucose by Merck Group
Sourced in United States, Germany, United Kingdom, China, Australia, France, Italy, Canada, Sao Tome and Principe, Japan, Macao, Israel, Switzerland, Spain, Belgium, India, Poland, Sweden, Denmark, Norway, Ireland, Mexico, New Zealand, Brazil, Singapore, Netherlands
D-glucose is a type of monosaccharide, a simple sugar that serves as the primary source of energy for many organisms. It is a colorless, crystalline solid that is soluble in water and other polar solvents. D-glucose is a naturally occurring compound and is a key component of various biological processes.
5
Humulin r by Eli Lilly
Sourced in United States, Japan, Canada, Brazil, Denmark, France
Humulin R is a laboratory product manufactured by Eli Lilly. It is a human insulin solution used for research and development purposes.
6
Accu check by Roche
Sourced in Switzerland, Germany, United States, France, United Kingdom, Australia, Brazil, Spain, Japan, Sweden, Canada, Poland, China
The Accu-Chek is a blood glucose monitoring system designed to measure and display the level of glucose in a person's blood. It provides a convenient and accurate way to monitor blood glucose levels for individuals with diabetes or those who need to regularly track their blood sugar.
7
Accu chek active by Roche
Sourced in Germany, Switzerland, United States, Brazil, Ireland, France, China, Japan
Accu-Chek Active is a blood glucose monitoring system designed to help individuals manage their diabetes. It is a compact and portable device that allows users to quickly and conveniently measure their blood glucose levels.
8
Glucometer by Roche
Sourced in Germany, Switzerland, United States, China, Australia, France, India
The Glucometer is a compact, handheld device used to measure and monitor blood glucose levels. It provides a quick and convenient way for individuals to check their glucose levels at home or on the go.
9
Onetouch ultra by LifeScan
Sourced in United States, France, United Kingdom, Canada
The OneTouch Ultra is a blood glucose monitoring device designed to measure the level of glucose in a user's blood. It provides accurate and reliable results to help individuals manage their diabetes.
10
Accu chek aviva by Roche
Sourced in Switzerland, United States, Germany, United Kingdom, Japan, Canada, Sweden, Spain, Belgium
The Accu-Chek Aviva is a portable blood glucose monitoring system designed for people with diabetes. It features a compact and easy-to-use design, allowing users to quickly check their blood sugar levels.

More about "Blood Glucose"

Blood sugar, plasma glucose, glycemia, hexose, dextrose, glucose monitoring, glucose homeostasis, glucose metabolism, glucose tolerance, glucose intolerance, hyperglycemia, hypoglycemia, diabetes mellitus, insulin, glucagon, glucose oxidase, glucose dehydrogenase, continuous glucose monitoring (CGM), self-monitoring of blood glucose (SMBG), HbA1c, fasting blood glucose, postprandial blood glucose, glycemic index, glycemic load, carbohydrate counting, Hemacue, Glucocard, Accu-Check, OneTouch, FreeStyle, Contour, Breeze.
Blood glucose is a critical measure of health and wellness.
It represents the concentration of the simple sugar glucose circulating in the bloodstream, which serves as the primary energy source for the body's cells.
Maintaining normal blood glucose levels is essential for proper bodily function and is tightly regulated by insulin, glucagon, and other hormones.
Imbalances in blood glucose can lead to serious conditions like diabetes, hypoglycemia, and hyperglycemia.
Effective monitoring and management of blood glucose is crucial for disease prevention and optimal health.
Numerous devices and technologies, such as glucometers (e.g.
Accu-Chek, OneTouch Ultra), continuous glucose monitors (CGMs), and laboratory tests (e.g.
HbA1c) are available to measure and track blood glucose levels.
Understanding blood glucose dynamics, including the impacts of diet, exercise, and medication, empowers individuals to take control of their health and wellness.